Star Therapeutics announced USD 200 million in private financing on 23 October 2026, co led by OrbiMed and Janus Henderson Investors. The South San Francisco biotechnology company develops therapies through a portfolio of focused subsidiaries. Founder and chief executive Adam Rosenthal leads the group, whose programmes include treatments for bleeding disorders and other rare diseases. Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile Group, Sofinnova Investments and Soleus Capital also participated. The announcement does not identify a conventional Series stage, so the round remains classified as undisclosed.
Star Therapeutics raises USD 200 million for rare disease medicines
OrbiMed and Janus Henderson Investors co lead the financing.

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


